For sure, volume is not normal. This is too crazy. I think data release this week or next week. Someone is probably working on a PR or internal communication leak.
Are you for real? You're complaining about a move from .27 to .41c in a month? This thing will continue to go up until phase 3 release. It doesn't even look like end of June but rather mid June latest. And if it goes up it wiill go up to 500 M market cap after the release.
Blinded before the extension is what I was getting at. There is obviously some confidence here as to whether or not there is a clinical effect for patients to continue to open label. Investigators are recommending their patients to participate.
This is not an oncology company so no...F-R rule doesn't apply here. However, it shares similarities in that VOC drugs are limited so the pricing of drugs is higher.
Extension studies are always a good sign. It's costly...there needs to be a degree of confidence on the part of the company and investigators though all parties are blinded. This means the effect of the drug must be obvious. Like others have mentioned...safety and whether repeats would be of concern are important for the filing.
Brendan relax! When I was on the CPXX board at less than 1.3, there were 3 longs and 1 short (multiple ids around 5-7). No one cared. I even sent a message to Adam. F via mailbag and he flat out said prediction: fail. Sonya C. bashed it too saying it's a scam. When positive results are released you will see a flux of people come in and you and I will be the original longs. MSTX is similar to CPXX in that their phase 3 should be viewed as an exploratory phase 2 that ran out of money. They still achieved a finding of significance for a particular sub-group. Have hope because the science is there. The science supports the mechanism. However, Mr. Market or funds will not want to touch this because it has been diluted and went through a phase 3 fail etc. It's better for most to invest after the data release.
The data release should be very close now. Database lock, QA check and stat analysis shouldn't be long. I liked that Culley released a pic on twitter as a public disclosure. This phase 3 will be as good as its phase 2.
I thought Sonya Colberg and Adam F.'s bashes were hilarious before data release. Absolutely zero analysis on the science SMH. What a bunch of hacks reading tea leaves and agreeing with market sentiment.
I tried helping a lot of longs and shorts on CPXX when I and like two other long investors warned shorts that it would be stupid to short at $1.3. I'll try helping people here as well with, "you are stupid if you short a $0.3 stock, no hedge fund will do it so don't do it. If you are cautious then wait for the phase 3 release and buy into the volume spike." Enjoy.
Because market cap shares diluted will still be $300-500 M. It will react that way because there are not treatments out there.
I had hoped that maybe they could draw from Biomarin's data and note the less than 1% dystrophin production as well the rate of mRNA production to make an AA but I don't think it will be enough.
I just reviewed Biomarin and hoped to go long on the basis that mRNA was being produced but no clear indication of meaningful dystrophin or patient walk performance. Biomarin had a better run trial, better data but poor safety. I had to ask myself if this as a risk/benefit question if I had to compare between Biomarin and Sarepta and the answer is no. The FDA are only concerned with efficacy and even Biomarin's data wasn't convincing enough to overcome safety. I won't go long as I don't believe the FDA will approve. Buying puts...